Rilpivirine vs. Efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less: Week 48 phase III analysis

AIDS

Volumn 27, Issue 6, 2013, Pages 889-897

  Molina, Jean Michel ^a,b   Clumeck, Nathan ^c   Redant, Karla ^d   Rimsky, Laurence ^d   Vanveggel, Simon ^d   Stevens, Marita ^d  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Baseline viral load; Efavirenz; Nonnucleoside reverse transcriptase inhibitor; Rilpivirine; TMC278; Treatment naive

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA AMYLASE PANCREAS ISOENZYME; ASPARTATE AMINOTRANSFERASE; CREATININE; EFAVIRENZ; ETRAVIRINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; RILPIVIRINE; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NAUSEA; NIGHTMARE; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NITRILES; PYRIMIDINES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84876418846     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835e1554     Document Type: Article

References (27)

1. Prescribing information for EDURANT (rilpivirine) tablets. Janssen-Cilag; December 2012. http://www.edurant-info.com/sites/default/files/EDURANT-PI.pdf http://www.accessdata.fda. gov/drugsatfda-docs/label/2011/202022s000lbl.pdf. [Accessed 8 January 2013].
2. EDURANT (rilpivirine) tablets. Summary of product characteristics. Janssen-Cilag; December 2012. http://www.medicines.org.uk/EMC/medicine/25490/ SPC/Edurant25mg/[Accessed 8 January 2013].
3. Prescribing information for COMPLERA (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets. Gilead Sciences; August 2012. http://www.gilead.com/pdf/complera-pi.pdf. [Accessed 8 January 2013].
4. EVIPLERA (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets. Summary of product characteristics. Gilead Sciences; October 2012. http://www.medicines.org.uk/EMC/medicine/25518/SPC/ Eviplera+200+mg+25+mg+245+mg+film+coated+tablets/[Accessed 8 January 2013].
5. Molina J-M, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378:238-246.
6. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, noninferiority trial. Lancet 2011; 378:229-237.
7. Cohen C, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naïve, HIV-1-infected patients: pooled results from the phase 3 double-blind, randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr 2012; 60:33-42.
8. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439-2448.
9. Walmsley S, Antela A, Clumeck N, et al. Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/ emtricitabine/efavirenz: 48-week results - SINGLE (ING114467). 52nd Interscience Conference on Antimicrobials and Chemotherapy; San Francisco, CA; 9-12 September 2012. Abstract H-556b.
10. Molina J-M, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, Neal D, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53:323-332.
11. Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, et al. Efficacy and safety of once-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment naïve HIV-1-infected patients at week 48. AIDS 2008; 22:1389- 1397.
12. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based vs efavirenz-based combination therapy in treatment naïve patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806.
13. Lima VD, Gill VS, Yip B, Hogg RS, Montaner JS, Harrigan PR. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. J Infect Dis 2008; 198:51-58
14. Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, et al. Efficacy and safety of etravirine in treatment experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009; 23:2289-2300.
15. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1- infected patients (ACTG A5262). AIDS 2011; 25:2113-2122.
16. Eron JJ Jr, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: A randomised, active-controlled, phase 3 noninferiority trial. Lancet Infect Dis 2011; 11:907-915.
17. Vingerhoets J, Rimsky L, Van Eygen V, Nijs S, Vanveggel S, Boven K, et al. Screening and baseline mutations in the TMC278 phase III trials ECHO and THRIVE: prevalence and impact on virological response (abstract 41). Antivir Ther 2011; 16 (Suppl 1):A51.
18. FDA Guidance for Industry. Antiretroviral drugs using plasma HIV RNA measurements: clinical considerations for accelerated and traditional approval, prepared by the Division of Antiviral Drug Products - Office of Drug Evaluation IV in the Centre for Drug Evaluation and Research (CDER), Appendix B; October 2002. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070968.pdf. [Accessed 8 January 2013].
19. Johnson VA, Brun-Vézinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17:138-145.
20. Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 2012; 59:39-46.
21. Division of Acquired Immune Deficiency Syndrome (DAIDS) table for grading the severity of adult and pediatric adverse events. Version 1; 28 December 2004. Available at: http://rsc.tech-res.com/safetyandpharmacovigilance. [Accessed 8 January 2013].
22. Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M, et al. Efficacy and safety of TMC278 in antiretroviral- naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 2010; 24:55-65.
23. Kulkarni R, Babaoglu K, Lansdon EB, Rimsky L, Van Eygen V, Picchio G, et al. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J Acquir Immune Defic Syndr 2012; 59:47-55.
24. Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, Wainberg MA. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol 2011; 85:11300-11308.
25. Hu Z, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol 2011; 85:11309-11314.
26. Picchio G, Vingerhoets J, Tambuyzer L, Coakley E, Haddad M, Witek J. Short communication: prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States. AIDS Res Hum Retroviruses 2011; 27:1271-1275.
27. Tambuyzer L, Nijs S, Daems B, Picchio G, Vingerhoets J. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr 2011; 58:18-22.